podcast
Investment Companies
edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Newron Pharmaceuticals has announced a new composition of matter patent for its lead schizophrenia candidate, evenamide. The patent was issued by the European Patent Office and claims crystalline forms of the drug candidate, processes for its preparation and its uses. The patent should provide protection to 2044.
Evenamide is currently being evaluated in the registrational Phase III ENIGMA programme, which has been designed to enrol at least 1,000 schizophrenia patients. Top-line results are expected in Q426, representing a significant upcoming inflection point for the company.
Healthcare | Comment
Consumer | Comment
Investment Companies | Comment
Healthcare | Comment
Healthcare | Comment
Get access to the very latest content matched to your personal investment style.